financetom
Business
financetom
/
Business
/
--Super Micro Computer Expects Q1 Sales of $5.9-$6.0 Billion, vs Prior Guidance of $6.0-$7.0 Billion and CIQ Analyst Consensus of $6.4 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Super Micro Computer Expects Q1 Sales of $5.9-$6.0 Billion, vs Prior Guidance of $6.0-$7.0 Billion and CIQ Analyst Consensus of $6.4 Billion
Nov 9, 2024 11:04 AM

04:30 PM EST, 11/05/2024 (MT Newswires) --

Price: 28.27, Change: +0.57, Percent Change: +2.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Fifth Era Acquisition Corp I Files For IPO- SEC FILING
BRIEF-Fifth Era Acquisition Corp I Files For IPO- SEC FILING
Jan 31, 2025
Jan 31 (Reuters) - FIFTH ERA ACQUISITION CORP I: * FIFTH ERA ACQUISITION CORP I - FILES FOR IPO * BLANK CHECK COMPANY FIFTH ERA ACQUISITION CORP I FILES FOR IPO OF UP TO $200 MILLION - SEC FILING * FIFTH ERA ACQUISITION CORP I - INTEND TO APPLY TO HAVE UNITS LISTED ON NASDAQ UNDER SYMBOL FERAU, * FIFTH...
Portugal says Novo Banco IPO likely to be for stake of up to 30%
Portugal says Novo Banco IPO likely to be for stake of up to 30%
Jan 31, 2025
LISBON (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than seek a full sale, Finance Minister Joaquim Miranda Sarmento said on Friday. In September, three sources with knowledge of the matter told Reuters that Lone Star, which...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Jan 31, 2025
Vertex Pharmaceuticals Inc. ( VRTX ) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy. What To Know: The company secured FDA approval for JOURNAVX, a non-opioid oral pain signal inhibitor for acute pain. This marks the first approval of a new class of pain medication in more than...
Intel's Growth Hinges on Fixing Products, Manufacturing, BofA Says
Intel's Growth Hinges on Fixing Products, Manufacturing, BofA Says
Jan 31, 2025
11:19 AM EST, 01/31/2025 (MT Newswires) -- Intel's ( INTC ) issues in product execution and manufacturing efficiency remain significant hurdles, with its future growth dependent on addressing weak central processing unit volumes, continued high costs, and delays in product launches, BofA Securities said in a note Friday. The firm said it lowered its 2025 and 2026 earnings per share...
Copyright 2023-2026 - www.financetom.com All Rights Reserved